Corvus' eczema pill shows early promise with strong skin-improvement signals
TL;DR Summary
Corvus Pharmaceuticals reports encouraging early-stage results for its oral eczema treatment soquelitinib: after eight weeks, 75% of treated patients reached EASI-75 and 33% achieved clear or almost clear skin versus 20% and none on placebo, suggesting potential superiority to Dupixent, though data are preliminary and from a small trial.
- Corvus pill shows promise in early-stage eczema trial statnews.com
- Why Small Biotech Stock Corvus Pharma Just Launched To An Eight-Year High Investor's Business Daily
- Soquelitinib Phase 1 Data Show Sustained Clinical Improvement With Extended Treatment in AD Dermatology Times
- Corvus challenger to Dupixent, JAKs gains ground in early atopic dermatitis study FirstWord Pharma
- Crypto: Is CRVS About to Break Out? The Chart Pattern Nobody's Discussing InteractiveCrypto
Reading Insights
Total Reads
0
Unique Readers
2
Time Saved
2 min
vs 3 min read
Condensed
90%
469 → 49 words
Want the full story? Read the original article
Read on statnews.com